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INTRODUCTION 
  
Analytical Chemistry, which is both theoretical and a practical science, 
is practiced in a large number of laboratories in many diverse ways. Methods of 
analysis are routinely developed, improved, validated, collaboratively studied 
and applied.  
Quality assurance plays a central role in determining the safety and 
efficacy of medicines. High specific and sensitive analytical techniques hold 
the key to the design, development, standardization and quality control of 
medicinal products. Quality level of any analytical work in a quality control 
laboratory depends on expertise of the analyst, most appropriate analytical 
procedure and overall performance of the analytical instruments. The main task 
in the pharmaceutical analyst is therefore to provide reliable analytical data 
rapidly and as accurate as required, repeatedly (or daily) at low cost and on a 
wide range of different samples, substances and materials. 
The analytical chemist is often confronted with the difficulty of 
selecting the most suitable method for the required determination.  
Modern analytical chemistry has most diverse methods and techniques 
of analysis for quantitative determination. Their classification is based on 
different principles.  
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They are broadly classified in to 
 Chemical methods of analysis 
 Physical methods of analysis 
Chemical Methods 
It involves the measurement of the mass of the substance or the volume 
of the reacting solutions.  Eg : Gravimetric and volumetric methods 
Physical Methods 
It involves the measurement of physical parameters of the system, which 
is related to the amount of component being determined. 
Eg : Spectral methods and electrochemical methods. 
Instrumental or physico chemical methods are based on the theory or 
relationship between the content and the corresponding physicochemical and 
physical properties of the chemical system being analyzed. 
The five important techniques that are indispensable to analytical 
chemistry are 
 Gravimetric Analysis 
 Volumetric Analysis 
 Optical Methods 
 Electrical Methods 
 Separation Methods 
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SPECTROSCOPY 
It is the measurement and interpretation of electromagnetic radiations 
absorbed or emitted when the molecules or atoms or ions of the sample 
undergo transition from one energy state (Ground state) to another (Excited 
state). 
It is of two types. 
1. Absorption Spectroscopy 
Where absorption of electro magnetic radiation (EMR) takes place. 
(Eg) UV Spectroscopy, Colorimetry, IR Spectroscopy, etc., 
2. Emission Spectroscopy 
Where emission of radiation is being studied. (Eg) Flame photometry 
flourimetry. 
CHROMATOGRAPHY  
Chromatography is a powerful separation method, which finds 
application in all branches of science. Chromatography was invented and 
named by the Russian botanist Mikhail Tswett at the beginning of the twentieth 
century. He employed this technique to separate plant pigments such as 
chlorophylls, Xanthophylls using glass columns packed with finely divided 
calcium carbonate. The separated species appeared as coloured bands on the 
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column, which accounted for the Greek name, he chose for the method as 
“chroma” meaning “colour” and “graphein” meaning to “write”.1 
In all chromatographic separations the sample is transported in a mobile 
phase, which may be a gas, liquid, or a supercritical fluid. This mobile phase is 
then forced through an immiscible stationary phase, which is fixed in place in a 
column or on a solid surface. The two phases are chosen, so that the 
components of the sample distribute themselves between the mobile and 
stationary phase to varying degrees. Those components that are strongly 
retained by the stationary phase, move only slowly with the flow of mobile 
phase. In contrast, components that are weakly held by the stationary phase 
travel rapidly. As a consequence of these differences in mobility, sample 
components separate into discrete bands as zones, that can be analysed 
qualitatively and / or quantitatiavely. 1 
Chromatographic methods can be classified according to the nature of 
the stationary and mobile phases.  
The different types of chromatography are  
1. Adsorption chromatography  
2. Partition chromatography   
3. Ion exchange chromatography  
4. Size exclusion or gel permeation chromatography.  
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The modern instrumental techniques of GLC, HPTLC and HPLC 
provide excellent separation and allow accurate assay of very low 
concentrations of wide variety of substance in complex mixtures. 
VALIDATION2,3,4 
Validation of an analytical method is the process that establishes, by 
laboratory studies, that the performance characteristics of the method meet the 
requirements for the intended analytical applications2. 
REASONS FOR VALIDATION 
¾ Enables scientists to communicate scientifically and effectively on 
technical matters. 
¾ Setting standards of evaluation procedures for checking complaints and 
taking remedial measures  
¾ Retrospective validation is useful for trend comparison of results 
compliance to cGMP/GLP. 
¾ Closer interaction with pharmacopoeia harmonization particularly in 
respect to determination of impurities and their limits.  
¾ For taking appropriate action, in case of non – compliance. 
¾ To provide high degree of confidence that the same level of quality is 
consistently built into each unit of finished product from batch to batch.  
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¾ Economic: The consistency and reliability of validated analytical 
procedure is to produce a quality product with all the quality attributes, 
thus providing indirect cost saving from reduced testing or re testing and 
elimination of product rejection. 
¾ As quality control process is not static, some form of validation / 
Verification should continue till the validated process is in use.  
Typical Analytical Characteristics used in Method Validation2   
 Accuracy 
 Precision 
 Specificity 
 Detection limit 
 Quantitation limit 
 Linearity  
 Range 
 Ruggedness 
 Robustness 
 System suitability 
Accuracy  
The accuracy of an analytical procedure expresses the closeness of the 
test results obtained by that method to the true value (a conventional true value 
or an accepted reference). 
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Accuracy is calculated as the percentage of recovery by the assay of the 
known added amount of analyte in the sample, or as the difference between the 
mean and the accepted true value, together with confidence intervals. 
The ICH documents recommend that accuracy be assessed using a 
minimum of nine determinations over a minimum of three concentration level 
covering the specified range (i.e., three concentrations and three replicates of 
each concentration.) 
Precision  
The precision of an analytical procedure is the degree of agreement 
among the individual test results when the method is applied repeatedly to 
multiple samplings of a homogenous sample under the prescribed conditions. 
Precision of an analytical procedure is usually expressed as the standard 
deviation or relative standard deviation (coefficient of variation) of a series of 
measurements. Precision may be a measure of either the degree of 
reproducibility or repeatability of the analytical method under operating 
conditions. 
¾ Repeatability refers to the use of the analytical procedure within the 
laboratory over a short period of time using the same analyst with same 
equipment. 
¾ Reproducibility refers to the use of analytical procedure in different 
laboratories as in a collaborative study. 
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¾ Intermediate Precision expresses within laboratory variation, as on 
different days or with different analysts or equipment within the same 
laboratory. 
ICH documents recommends that repeatability should be assessed using 
a minimum of nine determinations covering the specified range for the 
procedure (i.e., three concentration and three replicates of each concentration) 
or a minimum of six determination at 100% of the test concentration. 
Specificity  
Specificity is the ability to assess unequivocally the analyte in the 
presence of components, which may be expected to be present. Lack of 
specificity of an individual analytical procedure may be compensated by other 
supporting analytical procedures. 
Detection limit  
The detection limit of an individual analytical procedure is the lowest 
amount of analyte in a sample, which can be detected but not necessarily 
quantitated as an exact value. 
Based on the standard deviation of the response and the slope, the 
detection  
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Limit (LOD) may be expressed as 
 3.3 σ 
DL = 
     S 
Where,   
σ = standard deviation of the response 
S= slope of the calibration curve (of the analyte) 
Quantitation limit  
The quantitation limit of an analytical procedure is the lowest amount of 
analyte in a sample, which can be quantitatively determined with suitable 
precision, accuracy and reliability by the proposed method. 
Based on the standard deviation of the response and the slope, 
quantitation limit may be expressed as  
    10 σ 
LOQ = 
      S 
Where,  
σ = standard deviation of the response  
S = slope of the calibration curve (of the analyte) 
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Linearity  
Linearity of an analytical method is its ability to elicit the results that are 
directly or by a well-defined mathematical transformation proportional to the 
concentration of analyte in sample within a given a range. 
Range  
Range of an analytical procedure is the interval between the upper and 
lower levels of analyte (including these concentrations) that has been 
demonstrated to be determined within a suitable level of precision, accuracy 
and linearity using the method as written. 
Ruggedness 
The ruggedness of an analytical method is the degree of reproducibility 
of test results obtained by the analysis of the same samples under variety of 
conditions, such as different laboratories, analysts, instruments, lots of 
reagents, elapsed times, assay temperatures or days. Intermediate precision can 
be considered as ruggedness. 
Robustness 
The robustness of an analytical method is a measure of its capacity to 
remain unaffected by small but deliberate variations in method parameters and 
provides an indication of its reliability during normal usage.  
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System suitability3  
System suitability tests, plays a fundamental role in all the analytical 
procedures, are based on the concept that the equipment, electronics, analytical 
operations and samples to be analyzed constitute an integral system that can be 
evaluated as such. 
The system suitability tests are an integral part of gas and liquid 
chromatographic methods. 
¾ Retention time (Rt) is the time of emergence of the maximum of a 
component after injection. 
¾ Symmetry factor (or) tailing factor (T) is a measure of peak 
symmetry, is unity for perfectly symmetrical peaks. Its value increases 
as tailing become more pronounced. As peak asymmetry increases, 
integration and hence precison, becomes less reliable. 
  W0.05 
T   = 
  2f 
The assessment of peak shape is in terms of symmetry factor. 
W0.05  = width of the peak at 5% height. 
f = distance from the peak maximum to the leading edge of the peak,  
when measured at 5% peak height (from the baseline). 
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¾ Number of theoretical plates (N) is measure of column efficiency. If 
the number of theoretical plate is high, the column is said to be highly 
efficient and vice versa. It is a measure of sharpness, which is important 
for the detection of trace elements. 
       t          2 
         N =  5.54 
    wh/2 
The assessment of performance of efficient of a column is in terms of 
the number of theoretical plates.  
¾ Resolution  is a measure of relative separation of two peaks. Resolution 
is defined as the distance between the two band centres divided by the 
average width of the peaks determined at the bases of peaks. 
            2(t2-t1) 
R =      
           W2+W1 
Where,  
t2, t1 are retension times of first component and 2nd component 
respectively.  
W2 , W1 are width of peak of first component and 2nd component, 
eluted. 
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Statistical parameters 
Statistics consist of a set of methods and rules for organizing and 
interpreting observations. 
The precision or reproducibility of the analytical method was 
determined by repeating the analysis six times and the following statistical 
parameters were calculated. 
The Formulas are4  
     Σ(x – x )2 
Standard Deviation     = 
               n – 1 
      S.D 
R.S.D (%)  =    X 100 
       x 
 
        S.D 
S.E   =  
         n  
Confidence Interval / Limits (CI): 
The confidence limits describe the range within which we expect with 
given confidence the true value to lie.  
CL = x   ±  1.96 σ / n  
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Where , 
Σ = Sum of observations 
x  = Mean or arithmetic average (Σx / n) 
x = Individual observed value 
x – x  = Deviation of a value from the mean 
n = Number of observations 
S.D =  Standard deviation 
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DRUG PROFILE 
I.  FINASTERIDE5 
Finasteride is 4-azaandrost-1-ene-17-carboxamide,N-(1,1-dimethylethyl) 
-3-oxo-,(-,(5α,17β)-. The empirical formula of finasteride is C23H36N2O2 and 
its molecular weight is 372.55.  
Its structural formula is:  
 
Description 
Finasteride is a white crystalline powder with a melting point near 
250°C.  
Solubility 
It is freely soluble in chloroform and in lower alcohol solvents but is 
practically insoluble in water. 
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Mechanism of Action 
Finasteride, a synthetic 4-azasteroid compound, is a competitive and 
specific inhibitor of steroid Type II 5α-reductase, an intracellular enzyme that 
converts the androgen testosterone into 5α-dihydrotestosterone (DHT). Two 
distinct isozymes are found in mice, rats, monkeys, and humans: Type I and II.  
Indications and usage 
Finasteride is indicated for the treatment of male pattern hair loss 
(androgenetic alopecia) in MEN ONLY. Safety and efficacy were 
demonstrated in men between 18 to 41 years of age with mild to moderate hair 
loss of the vertex and anterior mid-scalp area. Finasteride is not indicated in 
women and children  
Contraindications 
Finasteride use is contraindicated in women when they are or may 
potentially be pregnant, because of the ability of Type II 5α-reductase 
inhibitors to inhibit the conversion of testosterone to DHT, finasteride may 
cause abnormalities of the external genitalia of a male fetus of a pregnant 
woman who receives finasteride.  
Warnings 
Finsteride is not indicated for use in pediatric patients or women. 
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Exposure of women - risk to male fetus 
Women should not handle crushed or broken Finsteride tablets when 
they are pregnant or may potentially be pregnant because of the possibility of 
absorption of finasteride and the subsequent potential risk to a male fetus. 
Fiinsteride tablets are coated and will prevent contact with the active ingredient 
during normal handling, provided that the tablets have not been broken or 
crushed.  
II. TAMSULOSIN HYDROCHLORIDE6 
Tamsulosin HCl is (-)-(R)-5-[2-[[2-(o-Ethoxyphenoxy) ethyl]amino] 
propyl]-2-methoxybenzenesulfonamide, monohydrochloride. The empirical 
formula of tamsulosin HCl is C20H28N2O5S.HCl. The molecular weight of 
tamsulosin HCl is 444.98. Its structural formula is:  
 
Description 
Tamsulosin HCl occurs as white crystals that melt with decomposition 
at approximately 230°C.  
 24
Solubility 
It is sparingly soluble in water and in methanol, slightly soluble in 
glacial acetic acid and in ethanol, and practically insoluble in ether.  
Mechanism of action 
Tamsulosin hydrochloride is an antagonist of alpha1A adrenoceptors in 
the prostate. The symptoms associated with benign prostatic hyperplasia (BPH) 
are related to bladder outlet obstruction, which is comprised of two underlying 
components: static and dynamic.  
The static component is related to an increase in prostate size caused, in 
part, by a proliferation of smooth muscle cells in the prostatic stroma. The 
dynamic component is a function of an increase in smooth muscle tone in the 
prostate and bladder neck leading to constriction of the bladder outlet.  
Tamsulosin hydrochloride capsules are not intended for use as an 
antihypertensive drug. 
Indications and usage 
Tamsulosin hydrochloride capsules are indicated for the treatment of the 
signs and symptoms of benign prostatic hyperplasia (BPH). Tamsulosin 
Hydrochloride capsules are not indicated for the treatment of hypertension. 
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Contraindications 
Tamsulosin hydrochloride capsules are contraindicated in patients 
known to be hypersensitive to tamsulosin hydrochloride. 
Warnings 
The signs and symptoms of orthostasis (postural hypotension, dizziness 
and vertigo) and potential risk of syncope (as with other alpha-adrenergic 
blocking agents) were detected more frequently in Tamsulosin hydrochloride 
capsule treated patients.  
Precautions 
¾ General 
1.  Carcinoma of the prostate: Carcinoma of the prostate and BPH cause 
many of the same symptoms. These two diseases frequently co-exist. 
Patients should be evaluated prior to the start of Tamsulosin 
hydrochloride capsules therapy to rule out the presence of carcinoma of 
the prostate. 
2.  Intraoperative Floppy Iris Syndrome (IFIS) has been observed during 
cataract surgery in some patients treated with alpha-1 blockers, 
including Tamsulosin hydrochloride capsules.  
 26
3.  Drug-Drug Interactions with Tamsulosin Hydrochloride capsules: - 
should NOT be used in combination with other alpha-adrenergic 
blocking agents. 
- should be used with caution in combination with cimetidine, 
particularly at doses higher than 0.4 mg. 
- Caution should be exercised when concomitantly administered with 
warfarin. 
- Caution should be exercised while operating machinery or driving due 
to possibiliity of postural hypotension such as dizziness as side effect of 
the drug. 
¾ Special precautions 
1. Pregnancy 
Teratogenic Effects, Pregnancy Category B. 
Tamsulosin Hydrochloride capsules are not indicated for use in women. 
2. Nursing Mothers and Pediatric Use 
Tamsulosin Hydrochloride capsules are not indicated for use in women and in 
pediatric populations. 
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OBJECTIVE OF STUDY 
In view of the literature cited, for the simultaneous quantification of 
Finasteride and Tamsulosin hydrochloride in pharmaceutical dosage forms, 
there is no documentary evidence available. At the outset, it was aimed to 
develop a rapid, sensitive, precise and accurate method for the pharmaceutical 
dosage forms. 
The objective of the study is as follows: 
 Development of rapid, sensitive and accurate reverse phase RP-HPLC 
method for simultaneous estimation of Finasteride & Tamsulosin 
hydrochloride in pharmaceutical dosage forms. 
 Development of rapid, sensitive and accurate High Performance Thin 
Layer Chromatographic method for simultaneous estimation of 
Finasteride & Tamsulosin hydrochloride in pharmaceutical dosage 
forms. 
 Development of UV Spectrophotometric method for simultaneous 
estimation of Finasteride & Tamsulosin hydrochloride in pharmaceutical 
dosage forms by Q-absorbance ratio method. 
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REVIEW OF LITERATURE 
Carlin-JR et al7 (1988) described a sensitive and selective HPLC 
method with UV detection for the quantitative determination of MK-906  
(N-(2-methyl-2-propyl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; 
finasteride) in human plasma.  Human plasma levels were reported for the drug 
following single dose oral administration of 50, 200 and 400 mg; urinary 
excretion data were reported for a single volunteer given 400 mg of drug. 
Soeishi-Y et al8 (1990) reported a simple, precise and sensitive HPLC 
method with fluorescence detection for the determination of Tamsulosin 
hydrochloride in human plasma.  The utility of the method was demonstrated 
by monitoring the plasma concentration of unchanged drug after oral 
administration of 0.2 mg of the drug to 12 healthy volunteers.  
Constanzer-ML et al9 (1991) developed a simple, specific and sensitive 
HPLC method with UV detection is described for the quantitation of finasteride 
in human plasma.  The method was used to determine the plasma drug level in 
a human subject following oral administration with 5 mg finasteride.   
Ryan-JA et al10 (1991) published a mid-infrared diffuse reflectance 
spectroscopic method for the rapid verification of identity and content of drugs 
in dosage forms.  The method was applied to the analysis of simvastatin, 
enalapril maleate, lovastatin and finasteride in dosage forms.   
Hiroshi Matsushima et al11 (1997) reported a highly sensitive method 
for the determination of tamsulosin hydrochloride, in human plasma dialysate, 
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plasma and urine by using liquid chromatography–electrospray tandem mass 
spectrometry (LC–MS–MS). Plasma dialysate, plasma and urine samples were 
extracted by brief liquid-phase extraction and analyzed using an HPLC system 
coupled to a mass spectrometer via an electrospray ionization interface. 
Selected reaction monitoring was used for the detection of tamsulosin and its 
internal standard. This method was validated in the concentration range  
10–1000 pg/ml in plasma dialysate, 0.5–50 ng/ml in plasma, and 1–100 ng/ml 
in urine with sufficient specificity, accuracy and precision.  
Syed-AA et al12(2001) reported, LC determination of finasteride and its 
application to storage stability studies. 
Ilango-K et al13 (2002) published a simple and sensitive method was 
developed for the estimation of finasteride in tablet formulations.  The method 
was based on the reaction of the drug with 0.2 % w/v 3-methyl-2-
benzthiazolinone hydrazone (MBTH) reagent in presence of 7% w/v ferric 
chloride solution to yield, a green colour, which had the characteristic light 
absorption in the visible region with an absorption maximum at 446 nm. The 
chromogen formed was stable for 45 min. Beer's law is obeyed in the 
concentration range of 2 to 10 mug/ml. The reproducibility of the method is 
98.8%. The proposed method was precise, accurate and reproducible and was 
extended to the analysis of finasteride in the tablet formulations.   
Loi-AL et al14 (2002) reported a retrospective chart review to facilitate 
the conversion of tamsulosin to formulary alpha-blockers in the treatment of 
benign prostatic hypertrophy; 
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Li-XY et-al15 (2003) developed the determination of finasteride in 
human plasma by HPLC-MS.  
HPLC-MS assay for determination of finasteride in human plasma and 
to investigate the bioequivalence in healthy volunteers was observed.  After 
alkalization with NaOH, plasma was extracted with ethyl acetate and separated 
using a C<INF>18</INF> column with a mobile phase of methanol-water 
(85:15). LC-ESI-MS was performed in the selected ion monitoring (SIM) mode 
using target ions at m/z 395 for finasteride and m/z 407 for IS. Fragmentor 
voltage was 120 V. Randomized crossover design was performed in 20 healthy 
volunteers. In the study periods, a single 10 mg dose of each tablet was 
administered to each volunteer. Result: Calibration curves were linear over the 
range 1-200mug/L. Limit of determination for finasteride in plasma was 
0.05mug/L. Recovery of finasteride from plasma was in the range of 85.9%-
98.7%. Results of variance analysis and two one-side t-test showed that there 
was no significant difference between two formulations in the AUC and 
C<INF>max</INF>. Conclusion made that the assay was sensitive, accurate 
and convenient. Two formulations were bioequivalent.     
Zhang-ZF et al16 (2004) developed A method for the chiral separation 
of tamsulosin isomers by high performance liquid chromatography using 
cellulose tris (3,5-dimethylphenylcarbamate) as a chiral stationary phase is 
described.  The precision, and calibration of the method is discussed.   
A high-performance liquid chromatographic (HPLC) method was 
developed for the chiral separation of an antagonist of alpha1A adrenoceptors, 
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tamsulosin and its S-isomer. Baseline separation of the isomers was achieved 
within 35 min on a CHIRALCEL OD-RH column with a binary solvent 
mixture of 50 mmol l−1 KPF6–acetonitrile (v/v (70:30), pH 5.0) as the 
optimized mobile phase. The detection limits and quantification limits of both 
R-isomer and S-isomer were 0.11 and 0.44 ng, respectively. The R.S.D. values 
of peak-area for the two isomer were 0.42% (of peak-height: 0.77%) for R-
isomer and 0.64% (of peak-height:0.92%) for S-isomer (n=5). 
Maier -V et al17 (2005) devised a method for Chiral separation of 
tamsulosin by capillary electrophoresis. 
Enantiomers of (±) 5-[2 (R,S)-{[2-(o-ethoxyphenoxy) ethyl] amino} 
propyl]-2-methoxy-benzenesulfonamide (tamsulosin, drug frequently used in 
the treatment of prostate diseases) were separated by capillary electrophoresis 
(CE). An acidic background electrolyte (BGE) with sulfated-β-cyclodextrin (S-
β-CD) was used to create a chiral separation environment. Baseline separation 
of the isomers was achieved during 5 min using cathodic electro-osmotic flow 
(EOF) (countercurrent mode). The quantification limits were 5.3 × 10−6 mol l−1 
for R-isomer and 5.7 × 10−6 mol l−1 for S-isomer. The R.S.D. values of peak 
area were 0.54% for R-isomer and 0.75% for S-isomer. The results achieved 
enable determination of 0.5% of optical impurity.  
Hulya Demir et al18 (2006) presented a liquid chromatography method 
and its analytical method validation for the determination of finasteride in the 
tablet form. 
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A quantitative method for finasteride by liquid chromatography (LC) 
with UV detector, was validated for its new tablet form Dilaprost®. Analysis 
was performed using Nova Pak C18 column at 60 °C. Detection was carried out 
at a wavelength of 210 nm. The best separation for finasteride peak was 
achieved by isocratic elution with the mobile phase water/acetonitrile/ 
tetrahydrofuran (80/10/10, v/v/v) and flow rate of 2 mL min−1. The sample 
volume injected into liquid chromatography system was 15 μL. Analytical 
method validation tests were performed. 
K. Basavaiah et al19 (2006) presented three sensitive spectrophotometric 
– bromatometric assay methods for the determination of finasteride in bulk and 
in tablets. The methods rely on the use of bromate-bromide reagent and three 
dyes namely, methyl orange, indigocarmine and thymol blue as reagents. They 
involve the addition of a measured excess of bromate-bromide reagent to 
finasteride in acid medium, and after the bromination reaction is judged to be 
complete, the unreacted bromine is determined by reacting with a fixed amount 
of either methylorange and measuring the absorbance at 520 nm (method A) or 
indigocarmine and measuring the absorbance at 610 nm (method B) or thymol 
blue and measuring the absorbance at 550 nm (method C). 
Pekka Keski-Rahkonen et al20 (2006) developed a simple, sensitive and 
selective LC–MS/MS method for the determination of tamsulosin in human 
aqueous humor and serum to study the recently reported eye-related adverse 
effects of this α1-blocker drug. Aqueous humor samples were analyzed by 
direct injection, after addition of the internal standard, labetalol. Liquid–liquid 
extraction with ethyl acetate was used for serum sample preparation. The 
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chromatographic separation was performed on a reversed phase column by 
gradient elution with acetonitrile −0.1% formic acid at a flow-rate of 
0.2 ml/min. 
USP 2921 exhibits a RP-HPLC assay method for Finasteride Tablets as 
an offical monograph. The method was established with L1 columns, 
Acetonitrile: Phosphoric acid (2.5mM) in 1:1 ratio as mobile phase and UV 
detector wavelength as 240nm for estimation of the drug in tablets.                                              
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MATERIALS AND METHODS 
 
EXPERIMENTAL DETAILS 
The following methods were developed for the Simultaneous estimation 
of Finasteride and Tamsulosin Hydrochloride in Pharmaceutical dosage forms. 
¾ Reverse Phase High Performance Liquid Chromatography 
¾ High Performance Thin Layer Chromatography. 
¾ Q-absorbance ratio method by UV-Visible Spectrophotometry 
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 1.  Reverse Phase High Performance Liquid Chromatography  
High Performance Liquid Chromatography22, 23 is the most widely 
used of all the analytical separation techniques, owing to its sensitivity; its 
ready adaptability to accurate quantitative determinations; its suitability for 
separating non-volatile species or thermally fragile ones and its widespread 
applicability to substance like aminoacids, proteins, carbohydrates, drugs, 
terpenoids, antibiotics, steroids that are of prime interest to many field of 
science. The technique of HPLC was developed in the late 1960s and early 
1970s from the theoretical knowledge of already established principles of 
earlier chromatographic techniques. The technique is based on the modes of 
separation i.e., adsorption, partition (including reverse phase partition), ion-
exchange and gel permeation, but it differs from column chromatography in 
that the mobile phase is pumped through the packed column under high 
pressure. The principal advantages of HPLC compared to classical (gravity 
feed) column chromatography are improved resolution of the separated 
substances, faster separation times and the increased accuracy, precision and 
sensitivity with which the separated substances may be quantified. 
The apparatus of HPLC includes pump, injection systems, column, 
detectors, recorder and data output system. 
HPLC is one of the most versatile instrument used in the field of 
pharmaceutical analysis. It provides the following features. 
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1. High resolving power 
2. Speedy separation 
3. Continuous monitoring of the column effluent 
4. Accurate quantitative measurement 
5. Repetitive and reproducible analysis using the same column 
6. Automation of the analytical procedure and data handling 
In HPLC the analyst has a wide choice of chromatographic separation 
methodologies from normal to Reverse Phase and a whole range of mobile 
phases using isocratic or gradient elution techniques. 
Various detectors available for HPLC are electrochemical detectors, 
refractive index detectors, fluorescence detectors, radiochemical detectors, 
mass-sensitive detectors and Ultra-violet (UV) detectors. 
Reverse -Phase High Performance Liquid Chromatography 
 Reversed-phase chromatography refers to the use of a polar eluent with 
a non-polar stationary phase in contrast to normal-phase chromatography, 
where a polar stationary phase is employed with a non-polar mobile phase. 
 In reverse-phase liquid chromatography the stationary phase is prepared 
by chemically bonding a relatively non-polar group on to the stationary phase 
support. The most frequent non-polar group on to the stationary support is 
octadecylsilane (ODS or C18), which gives a highly lipophilic stationary phase. 
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Less lipophilic stationary phases are produced when octylsilance (C8, C2, 
phenyl or cyanoprophyl) – bonded phases are used. The shorter silanyl chain 
bonded phases (C2 and C8) are often most appropriate when highly lipophilic 
solutes are to be separated which would be highly retained on C18 column. 
Reversed-Phase Mobile phases 
 The power of HPLC in terms of being able to resolve many compounds 
is mainly due to the diversity of mobile phases or mobile solvents available. 
The mobile phases in reversed phase HPLC generally comprises of water and a 
less polar organic solvents, e.g. methanol or acetonitrile. The rate of elution of 
the components is controlled by the polarity of the organic solvents and its 
proportion in the mobile phase. Further selectivity in the separation of ionisable 
substances may be obtained by altering the pH of the mobile phase to cause ion 
suppression. The water should be of high quality either distilled or 
deminieralised. When inorganic salts and ionic surfactants are used, the mobile 
phase should be filtered before use since these additives frequently contain a 
significant amount of water insoluble contaminants that may damage the 
column. Reverse-phase mobile phases are generally non-inflammable due to 
high water content. Degassing is quite important with reversed-phase mobile 
phases. 
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A.  INSTRUMENTS 
High performance Liquid Chromatograph 
• Shimadzu Prominence separation module equipped with pumps LC-10AT 
• UV-Visible detector SPD 10A 
• Phenomenex column. Luna 5µ C18 – Spherical. Size: 250 x 4.60mm 
• Rheodyne valve injector with 20µl fixed loop 
Hamilton syringe (25µl syringe) 
Ultipor N66 (Nylon 6.6 membrane filter) 
pH meter – Digisun electronics 
Sonicator – Enertech electronics 
Electronic Balance -  Mettler AB 54. 
B.  REAGENTS AND CHEMICALS: 
Acetonitrile HPLC grade 
Water HPLC grade 
Disodium hydrogen orthophosphate anhydrous AR grade 
Orthophosphoric acid AR grade 
Finasteride USP – Preanalysed raw material 
Tamsulosin Hydrochloride  - preanalysed raw material 
Market sample of formulation from a local pharmacy 
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C.  OPTIMIZATION OF CHROMATOGRAPHIC CONDITIONS: 
The chromatographic conditions were optimized using C18 column and 
mobile phase was developed with acetonitrile and buffer (adjusted to pH 3) in 
different ratios.  
The retention time of Finasteride and Tamsulosin Hydrochloride were 
determined by injecting individual standard drug solutions separately. Then the 
mixed standard solutions of Finasteride and Tamsulosin Hydrochloride were 
prepared with the concentration in the ratio of 12.5:1 respectively. This stock 
solution was diluted to 100mcg and 8mcg of Finasteride and Tamsulosin 
Hydrochloride and then injected for all the trials made. In all the trials, the 
respective mobile phase are used as diluent. UV λmax of the individual drugs 
were determined at 210 nm for Finasteride and 225nm for Tamsulosin 
Hydrochloride. UV – visible Detector was used to detect the signals. 
Trial 
No. 
Mobile phase     λ 
(nm) 
Flow  
Rate 
(ml/min)
Observation 
1. ACN: Buffer 
(75:25 v/v)  
220  1.0 The Capacity factor of Tamsulosin 
Hydrochloride is 0.35. Finasteride 
peak was not significant. 
2. ACN: Buffer 
(75:25 v/v)  
230 0.75 The retension time of Tamsulosin 
was 2.0 minutes. The Finasteride 
peak had secondary peak near by. 
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Trial 
No. 
Mobile phase     λ 
(nm) 
Flow  
Rate 
(ml/min)
Observation 
3. ACN: Buffer 
(50:50 v/v)  
230  0.75 The retension time of Tamsulosin 
was 2.05 mins. The retension time 
of Finasteride was extended to 
8.79 minutes. 
4. ACN: Buffer 
(60:40 v/v)  
230 0.75 The retension time of Tamsulosin 
was 2.69 mins. The retension time 
of Finasteride was extended to 
7.79 minutes.  
5. ACN: Buffer 
(60:40 v/v)  
240 0.75 Tamsulosin peak was not 
prominent. 
6. ACN: Buffer 
(60:40 v/v)  
230 0.80 The retension time of Tamsulosin 
was 2.65 mins. The retension time 
of Finasteride was extended to 
7.11 minutes.  
 
D. OPTIMISED CHROMATOGRAPHIC CONDITIONS 
Stationary Phase: C18 (250 x 4.6mm, 5μ) Phenomenex 
Mobile phase: Acetonitrile : buffer  adjusted to pH 3 (60:40 v/v) 
Operation mode: Isocratic 
Wavelength of UV detector: 230nm 
Flow rate: 0.8ml/min 
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Diluent: Mobile phase 
Injection volume: 20μl 
Temperature: Ambient 
Run time: 10 minutes 
E. PREPARATION OF MOBILE PHASE 
Preparation of Buffer 
A quantity of 0.8875g (0.05mM) of disodium hydrogen orthophosphate 
anhydrous was dissolved in water and made up to 125ml with water. The pH 
was adjusted to 3.0 using Orthophosphoric acid and filtered through membrane 
filter applying vacuum. The mobile phase is prepared by mixing Acetonitrile 
and the buffer in the ratio of 60:40. 
F. EXPERIMENTAL 
The diluent was injected first to determine the absence of any 
interference with the baseline. The retention time of individual drugs are 
determined. Then the combination of drugs was injected in different 
concentrations and the chromatogram was developed under the optimized 
chromatographic condition. 
Preparation of standard solution 
About 125mg of Finasteride and 10mg of Tamsulosin Hydrochloride 
was weighed accurately and transferred into 25ml volumetric flask, dissolved 
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and diluted to volume with the mobile phase (ACN: Buffer – 60:40) to get the 
stock solution. From this serial dilutions were made to obtain a final 
concentration ranging from 50 – 150mcg/ml of Finasteride and 4-12mcg/ml of 
Tamsulosin Hydrochloride. Linearity was established in this concentration 
range (50 – 150%) and calibration curve was constructed, by injecting 20μl of 
the standard solutions. Linearity data are presented in Table No.1(a), 1(b) and 
the graphs are presented as Graph No.1(a), 1(b), 1(c) and 1(d). 
Market Sample Analysis 
The content of twenty capsules were accurately weighed and powdered. 
The powder equivalent to 12.5mg of Finasteride and 1mg of Tamsulosin 
Hydrochloride was accurately weighed and transferred into a 50ml volumetric 
flask. The content was dissolved in 25ml of mobile phase and subjected to 
sonication for 20 minutes. Then the resulting solution was made up to the 
volume with the mobile phase. This solution was filtered through a nylon 
membrane filter and first few ml of filterate was rejected. It was then diluted to 
yield a final solution, with the concentration of 100mcg/ml of Finasteride and 8 
mcg of Tamsulosin Hydrochloride, which is used for further estimations.  
The amount of drug present per capsule was calculated by adopting the 
following formula. 
 Area of Sample x Standard dilution x Average weight x Potency 
=    _____________________________________________________ 
     Area of Standard x Sample dilution  x 100 
The assay results are presented in the Table No.1(c)  
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Recovery Studies 
Recovery studies were carried out by addition of a known quantity of 
the standard drug to the pre-analyzed samples (50, 100 and 150% of target 
level) and the whole contents were reanalyzed by the proposed method. 
Percentage recovery was calculated by using the following formula:        
               Amt. found in solution – Actual amt. of preanalysed sample  
=  _________________________________________________  x 100      
                                     Amount of standard added 
The data are presented in Table No.1(e) and 1(f). 
METHOD VALIDATION 
1.  Specificity 
The Specificity is the ability to assess unequivocally the analyte in the 
presence of components that may be expected to be present, such as impurities, 
degradation products and matrix components. This definition implies the 
identification tests, purity test and assays. The drugs, Finasteride and 
Tamsulosin have specific retension time in the optimised chromatographic 
conditions. 
2.  Linearity and Range 
The linearity and range of the analytical method is determined from the 
calibration curve and mathematical transformations proportional to the 
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concentration of the analyte. The prepared standard stock solution is diluted to 
the concentration ranging from 50 to 150% (of 100% target level) of finasteride 
and Tamsulosin Hydrochloride. The data are presented in the Table No.1(a) 
and 1(b). 
3.  Precision (Method Precision, Intermediate Precision (Ruggedness)) 
Precision was evaluated by quantifying homogenous sample in six times 
for both intra-assay and inter-assay precision equivalent to 100µg/ml of 
Finasteride  and 8µg/ml of Tamsulosin hydrochloride. 
The amount of drug present per capsule was calculated by adopting the 
following formula. 
Area of Sample x Standard dilution x Average weight x Potency 
=    _____________________________________________________ 
     Area of Standard x Sample dilution  x 100 
The precision data are presented in the Table No.1(d) 
4.  Accuracy (Recovery) 
To ensure the accuracy of the method, recovery studies were carried out 
by addition of a known quantity of the standard drug to the pre-analyzed 
samples (50, 100 and 150% of target level) and the whole contents were 
reanalyzed by the proposed method. 
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Percentage recovery was calculated by using the following formula:   
              Amt. found in solution – Actual amt. of preanalysed sample  
=  __________________________________________________x 100 
Amount of standard added 
The data on recovery studies are presented in Table no.1(e) & 1(f). 
5.  Robustness 
The robustness of the assay method was with effect of buffer pH, pH 
adjusted ± 0.2 units (pH 2.8 and pH 3.2). The method complied with the system 
suitability parameters – System precision, No. Of Theoretical plates, 
Resolution and Tailing factor were with in the ICH specified limits.   
6.  System suitability parameters 
System suitability parameters are fundamental criteria in Gas and Liquid 
Chromatography. These parameters are performed before each analysis to 
verify that the results obtained are accurate and precise. 
The parameters are system precision, resolution, number of theoretical 
plates and Tailing factor. The data of these parameters are specified in Table 
No.1(g) 
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 2. High Performance Thin Layer Chromatography  
Izmailov and Shraiber (1938) first introduced the technique of thin layer 
chromatography for the separation of plant extracts using layer of alumina set 
on glass plate. TLC as a procedure for analytical adsorption chromatography 
was first introduced by Stahl (1958) who was mainly responsible for bringing 
out a standard equipment for preparing thin layers. Thin Layer chromatography 
can be used as a qualitative tool for separation of simple mixtures where low 
cost and simplicity are required, or else it can be used as a powerful separation 
tool for quantitative analysis, the later now referred to as HPTLC. It can 
simultaneously handle several samples even of divergent nature and 
composition.24 
High performance Thin Layer Chromatography enables the most 
complicated separations. The HPTLC plates are prepared from optimized (e.g., 
particle size and particle size distribution) adsorbent layers and extremely even 
surfaces. These plates offer greater separation efficiency through smaller plate 
heights than the conventional TLC plates. Shorter analysis times, detection 
limits in the nanogram range with the UV absorption detection and in the 
picogram range with flourimetric detection are some additional advantages 
with these plates. 24 
Steps involved in HPTLC25  
1. Selection of chromatographic layer  
2. Sample and standard preparation  
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3. Layer pre-washing  
4. Layer pre-conditioning  
5. Application of sample and standard  
6. Chromatographic development  
7. Detection of spots  
8. Scanning and Documentation of chromatic plate 
Sample application.      
 The samples to be chromatographed are applied to the chromatogram 
layer. Volume precision and exact positioning are ensured by the use of a 
suitable instrument. 
Chromatogram development 
 The solvent (mobile phase) migrates the predetermined distance in the 
layer (stationary phase) by capillary action. In this process, the samples are 
separated into fractions. After evaporation of the mobile phase, the fractions 
remain stored on the layer.    
Chromatogram evaluation 
 The tracks (samples) are scanned in a densitometer with a light beam in 
the visible or ultraviolet range of the spectrum. Absorbance or fluorescence is  
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measured by diffuse reflectance. Alternatively to classical densitometry, the 
chromatogram can be evaluated by video technology. Additional operations 
such as per or post-chromatographic derivatisation can be performed as 
required. 
HPTLC has become the accepted term for layer which 
• are slightly thinner than conventional layers(0.20mm instead of 0.25 
mm) and thus need less sample to show the same measuring result. 
• have a smaller mean grain size – 7 instead of 12-20 µm and in particular 
a closer grain size distribution than conventional layers. 
• hence give better resolution with a migration distance about 50%  
shorter-50mm as against 100-120mm. 
• and have improved optical properties over conventional layers which 
gives better accuracy during densitometric evaluation. 
A. INSTRUMENTS 
High Performance Thin Layer Chromatograph 
CAMAG HPTLC SCANNER II with wincats software 
Linomat IV Sample applicator 
Silicagel 60F 254 (MERK) precoated sheets 
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CAMAG Twin trough chamber 
Balance: Denver Instruments 
Centrifuge – Eltek Microspin TC 4815 D 
Sonicator – Enertech Electronics 
B. REAGENTS AND CHEMICALS 
Toluene AR grade 
Methanol AR grade 
Chloroform AR grade 
Triethylamine AR grade 
Ethyl acetate AR 
Formic acid AR 
Ammonia AR 
Silica gel G 
Iodine 
Active Pharmaceutical Ingredients – Finasteride and Tamsulosin 
Hydrochloride 
Market sample of formulation from a local pharmacy 
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C.  CHOICE OF SOLVENTS (Trials) 
Initial trials were made with the prepared TLC plates, glass plates coated 
with Silicagel G. The spots were identified using iodine to confirm the 
resolution of the drugs from the mixture. Individual drug standards are also 
spotted to determine the  Rf of each of the drugs. 
Trial 
No. Mobile Phase Ratio Observation 
1. Chloroform: EAC: 
Ammonia 
7:2.5:0.5 The two drugs did not resolve 
much 
2. Chloroform: EAC: 
Ammonia 
6:4:1.5 No proper resolution of the 
drugs from mixture spot. 
3. Chloroform: EAC: Water 6:3:1 No proper resolution of the 
drugs from mixture spot. 
4. Toluene: Chloroform: Water 7:2:1 Tailing of the spots 
5. Toluene: EAC: Methanol 6:3:1 The two drugs did not resolve 
much 
6. Toluene: Chloroform: 
Formic acid 
6:3:1 No separation of spots 
7.  Toluene: EAC: Formic acid 6:3:1 Separation of both drugs from 
the mixture. Distance 
travelled are: 
Solvent front – 7.25cm 
Finasteride – 2.4 cm; Rf: 
0.331 
Tamsulosin – 1.2 cm; Rf: 
0.166 
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Trial 
No. Mobile Phase Ratio Observation 
8. Toluene:Chloroform:Methanol 6:3:1 Both the drugs were resolved 
from the mixture spot. Distance 
travelled are: 
Solvent front – 8.5cm 
Finasteride – 3.8cm; Rf: 0.447 
Tamsulosin – 2.4cm; Rf: 0.282 
9. Toluene:Chloroform:Methanol 6:2:2 Both the drugs were resolved 
from the mixture spot. Distance 
travelled are: 
Solvent front – 8.7cm 
Finasteride – 3.9cm; Rf: 0.448 
Tamsulosin–2.55cm; Rf: 0.293 
Trials with precoated sheets and scanning in HPTLC scanner 
10. Toluene:Chloroform:Methanol 6:2:2 Streaking of the Tamsulosin 
spot. The peak shape was not 
proper.  
11. Toluene:Chloroform:Methanol: 
Triethylamine 
6:2:2:1 Streaking of the Tamsulosin 
spot was eliminated. But the 
resolution of drugs from the 
mixture was reduced.  
12. Toluene:Chloroform:Methanol: 
Triethylamine 
7:2:1:2 Streaking of the Tamsulosin 
spot was eliminated with good 
resolution of drugs   
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D.  OPTIMISED CHROMATOGRAPHIC CONDITION 
Stationary Phase: HPTLC Silicagel 60F 254 precoated (Merck) 
Mobile Phase: Toluene: Chloroform: Methanol: Triethylamine (7:2:1:2.0) 
Diluent: Methanol  
Plate dimension: 20 x 10 
Application mode: CAMAG Linomat IV 
Development mode: Twin trough chamber 
Saturation time: 20 minutes 
Temperature: Ambient 
Migration distance: 90mm 
Distance between tracks: 10.0mm 
Slit width: 5mm 
Slit length: 5mm 
Scanning speed: 4mm/sec 
Source of radiation: Deuterium 
Wavelength scanning: 230nm 
Wavelength increment: 5nm 
 53
E. EXPERIMENTAL 
Preparation of standard solution 
About 125mg of Finasteride and 10mg of Tamsulosin Hydrochloride 
was weighed accurately and transferred into 25ml volumetric flask, dissolved 
and made up to the volume with methanol to get the stock solution. From this 
serial dilutions were made to obtain a final concentration ranging from 500 – 
1500mcg/ml of Finasteride and 40-120mcg/ml of Tamsulosin Hydrochloride. 
Linearity was established in this concentration range and calibration curve was 
constructed, by injecting 25μl of the standard solutions. Linearity data are 
presented in Table No. 2(a), 2(b) and the graphs are presented as graph No.  
2 (a), 2(b), 2(c) and 2(d) 
Market Sample Analysis 
The content of twenty capsules were accurately weighed and powdered. 
The powder equivalent to 10mg of Finasteride and 0.8mg of Tamsulosin 
Hydrochloride was accurately weighed and transferred into a 10ml volumetric 
flask. The content was dissolved in 8ml of methanol and subjected to 
sonication for 30 minutes. This solution was then allowed to stand for 10 
minutes and made up to the volume with methanol. This final solution is 
centrifuged and exhibited the concentration of 1000mcg/ml of  
Finasteride and 80mcg/ml of Tamsulosin Hydrochloride, which is used 
for further estimations by spotting 25μl. 
 54
The amount of drug present per capsule was calculated by adopting the 
following formula. 
Area of Sample x Standard dilution x Average weight x Potency 
=    _____________________________________________________ 
     Area of Standard x Sample dilution  x 100 
The assay results are presented in the table No.2(c)  
Recovery Studies 
Recovery studies were carried out by addition of a known quantity of 
the standard drug to the pre-analyzed samples (50, 100 and 150% of target 
level) and the whole contents were reanalyzed by the proposed method. 
Percentage recovery was calculated by using the following formula:        
               Amt. found in solution – Actual amt. of preanalysed sample  
= __________________________________________________x 100      
                                    Amount of standard added 
The data are presented in table no. 2(e) and 2(f). 
METHOD VALIDATION 
1.  Specificity 
The Specificity is the ability to assess unequivocally the analyte in the 
presence of components that may be expected to be present, such as impurities, 
degradation products and matrix components. This definition implies the 
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identification tests, purity test and assays. The two drugs have specific 
retardation factor in the optimized chromatographic conditions. 
2.  Linearity and Range 
The linearity and range of the analytical method is determined from the 
calibration curve and mathematical transformations proportional to the 
concentration of the analyte. The prepared standard stock solution is diluted to 
the concentration ranging from 50 to 150% (of 100% target level) of finasteride 
and Tamsulosin Hydrochloride. The data are presented in the table No. 2(a) and 
2 (b). 
3.  Precision (Method Precision) 
Precision was evaluated by quantifying homogenous sample in six times 
for intra-day assay precision equivalent to 1000µg/ml of Finasteride and 
80µg/ml of Tamsulosin hydrochloride. 
The amount of drug present per capsule was calculated by adopting the 
following formula. 
Area of Sample x Standard dilution x Average weight x Potency 
=    _____________________________________________________ 
     Area of Standard x Sample dilution  x 100 
The assay results are presented in the table No.2(d)  
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4.  Accuracy (Recovery) 
To ensure the accuracy of the method, recovery studies were carried out 
by addition of a known quantity of the standard drug to the pre-analyzed 
samples (50, 100 and 150% of target level) and the whole contents were 
reanalyzed by the proposed method. 
Percentage recovery was calculated by using the following formula:   
              Amt. found in solution – Actual amt. of preanalysed sample  
 =                                                                                                  x 100      
                            Amount of standard added 
The data are presented in table no. 2(e) and 2(f). 
5.  Stability of drug solution 
The standard solution and sample solution were spotted after 24 hours to 
study the stability of the analyte in solution. Finasteride and Tamsulosin 
Hydrochloride were stable for up to 24 hours. 
6.  System suitability parameters 
System suitability parameters are fundamental criteria in Gas and Liquid 
Chromatography. These parameters (system precision, resolution, number of 
theoretical plates and Tailing factor) are performed before each analysis to 
verify that the results obtained are accurate and precise. 
The parameters considered for HPTLC are system precision, resolution 
factor, retardation factor and Tailing factor. The data of these parameters are 
specified in Table No. 2(g) 
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3. UV-Visible Spectrophotometric method  
(Q-Absorbance ratio method)  
 
UV - VISIBLE SPECTROSCOPY involves the measurement of amount of 
ultra-violet radiation absorbed by a substance in the solution. The wavelength 
between 190 – 390 nm (practically 200 – 400 nm) is considered to be UV 
radiations/ region. Colored compounds absorb in visible range i.e. 400-800 nm.  
The assay of an absorbing substance, can be carried out by using 
a) Standard absorptivity value. 
b) Use of calibration graph. 
c) Single point standardisation. 
The use of UV and visible spectroscopy for quantitative analysis 
employs the method of comparing the absorbance of standards and samples at a 
selected wavelength. The analysis of mixtures of two or more components is 
facilitated by activity of absorbance. Other applications include measurement 
of absorption of complexes to establish their composition. All chromogenic 
compounds are not suitable for quantitative measurements, i.e. the choice of the 
system and procedure depends largely on the chemistry of the species to be 
determined.26 
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Points to be considered in the selection of procedure include: 
¾ Stability of absorbance with respect to time, variation of pH, ionic 
strength and temperature. 
¾ Degree of selectivity of complexing agent includes the effect of other 
species likely to be present. 
¾ Conformity to the Beer-Lambert’s Law and plot calibration data for the 
range of concentration measured. 
In multi-component formulations, the presence of two or more drugs in 
a formulation give rise to interference components which mutually interfere 
with each other in their estimation. For the simultaneous estimation of drugs in 
such formulations many techniques have been applied. 
They are27 
1) Simultaneous equation method 
2) Absorbance ratio method 
3) Derivative spectroscopy method. 
4) Chemical Derivatisation Methods. 
5) Multi-component mode of analysis. 
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ABSORBANCE RATIO OR Q-ABSORBANCE METHOD27 
This method depends on the property of a substance, which obeys 
Beer’s law at all wavelengths, the ratio of absorbance at any two wavelengths 
is a constant value independent of concentration or path length. Two different 
dilutions of the same sample give the same absorbance ratio; this ratio is 
referred to as a ‘Q’ value. In quantitative assay of two components in a 
admixture by the absorbance ratio method, absorbances are measured at two 
wavelengths: one being the λmax of the components (λ2) and the other being a 
wavelength of equal absorptivity of the two components (λ1), i.e., iso-
absorptive point. Two equations are constructed.  
Equation 1: A1 = ax1 (Cx + CY) 
Equation 2: Cx = QM-QY / Qx - QY  x  A1/ ax1. 
Accurate dilutions of the sample solution and standard solutions (of the 
individual drugs) are necessary for the accurate measurements of A1 and ax1 
respectively.  
A1 and A2 are the absorbances of sample solution at λ2 and λ1  
X and Y are the two components present in sample solution.  
ax1 is the absorptivity of standard solution of component X at λ1 
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A. INSTRUMENTS 
UV-Visible Spectrophotometer – Shimadzu 1650 PC 
Balance – Mettler AB 54 
Sonicator – Enertech electronics 
Centrifuge – Remi clinical Model 854/4  
B. REAGENTS AND CHEMICALS 
Alcohol AR grade 
Distilled Water  
Active Pharmaceutical Ingredients – Finasteride USP; Tamsulosin 
Hydrochloride 
Market sample of formulation from a local pharmacy 
C. EXPERIMENTAL 
1.  Devising the solvent for the drugs 
Based on their solubility profile, the solvent mixture, ethanol 95% v/v 
and distilled water in ratio of 30:50 was selected for the spectrophotometric 
estimation. 
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2.  Establishment of various parameters 
(a)  Determination of Absorption maximum – λmax and isoabsorptive 
point 
Preparation of Standard Solutions 
About 25mg of Finasteride was accurately weighed and transferred to a 
25ml volumetric flask, dissolved completely using ethanol: water (3:5) and 
further made it to volume with same solvent to get the stock solution. From this 
serial dilution was made to obtain a final concentration of 10μg/ml. 
About 25mg of Tamsulosin hydrochloride was accurately weighed and 
transferred to a 25ml volumetric flask, dissolved completely using 
ethanol:water (3:5) and further made it to volume with same solvent to get the 
stock solution. From this serial dilution was made to obtain a final 
concentration of 10μg/ml. 
The solutions were scanned separately in the wavelength range of  
190 – 400nm and the spectrum was recorded for the individual standards. λ max 
of Finasteride was found to 205nm and that of Tamsulosin Hydrochloride was 
225nm. The overlay spectra of the two drugs show three isoabsorptive points: 
217.7nm, 239nm and 260nm. Of these, 217.7 nm was chosen for the 
estimation. 
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(b)  Beer’s Law Plot and Linearity 
From the stock solution of individual standard solutions of Finasteride 
and Tamsulosin Hydrochloride serial dilutions were made to obtain the 
concentrations ranging from 5-30μg/ml for Finasteride and 5-30μg/ml for 
Tamsulosin hydrochloride. The above solutions were scanned over the range of 
190nm to 400nm and the resultant spectra were recorded. The response versus 
concentration obeyed linear relationship, the line of best fit was found out by 
using line of linear regression equation.  
Y =  α + βx. 
  (ΣY) (ΣX2) – (ΣX) (ΣXY) 
α    = 
         NΣX2 – (ΣX)2 
NΣXY – (ΣX) (ΣY) 
 β =  
         NΣX2 – (ΣX)2 
Where, 
X  - Concentration µg/ml 
Y  - Response corresponding to concentration X 
α  - Intercept 
β  - Slope 
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Residuals of the responses were calculated and plotted against the 
concentration (x axis). It was found that the points were scattered randomly 
around zero of x axis. Subsequently LOD and LOQ values were determined 
from the plot. 
The data and graphs are presented as Table No, 3(a), 3(b) and Graph 
No.3(a), 3(b), 3(c) and 3(d) respectively.  
LOD = 3.3 x Standard deviation of residuals / slope 
LOQ = 10 x Standard deviation of residuals / slope 
ABSORBANCE RATIO OR Q-ABSORBANCE RATIO METHOD 
This method depends on the property of a substance, which obeys 
Beer’s law at all wavelengths, the ratio of absorbance at any two wavelengths 
is a constant value independent of concentration or path length. In quantitative 
assay of two components in a admixture by the absorbance ratio method, 
absorbances are measured at two wavelengths: one being the λmax of the 
components (λ2) and the other being a wavelength of equal absorptivity of the 
two components (λ1), i.e., iso-absorptive point. Two equations are constructed.  
Equation 1: A1 = ax1 (Cx + CY) 
Equation 2: Cx = QM-QY / Qx - QY  x  A1/ ax1. 
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Market Sample analysis 
Preparation of Sample solution 
The content of twenty capsules were accurately weighed and powdered. 
The powder equivalent to 5mg of Finasteride and 0.4mg of Tamsulosin 
Hydrochloride was accurately weighed and transferred into a 50ml volumetric 
flask. The content was dissolved in 25ml of ethanol- water (3:5) solvent 
mixture and subjected to sonication for 20 minutes. To this solution 5ml of 
Tamsulosin Hydrochloride Standard solution (1mg/ml) was added, mixed well 
and then allowed to stand for 2 minutes and made up to the volume with the 
same solvent. This final solution is centrifuged for 5 minutes and had the 
concentration of 10mcg/ml of Finasteride and 10.8mcg/ml of Tamsulosin 
Hydrochloride, which is used for further estimations.  
The amount of drug present per capsule was calculated by adopting the 
following formula. 
Area of Sample x Standard dilution x Average weight x Potency 
=    _____________________________________________________ 
     Area of Standard x Sample dilution  x 100 
The assay results are presented in the table No.3(c)  
Recovery Studies 
Recovery studies were carried out by addition of a known quantity of 
the standard drug to the pre-analyzed samples (50, 100 and 150% of target 
level) and the whole contents were reanalyzed by the proposed method. 
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Percentage recovery was calculated by using the following formula:        
Amt. found in solution – Actual amt. of preanalysed sample 
= ________________________________________________  x 100                        
 
Amount of standard added 
 
 
The data are presented in table no. 3(e) and 3(f) 
METHOD VALIDATION 
1.  Specificity 
The Specificity is the ability to assess unequivocally the analyte in the 
presence of components that may be expected to be present, such as impurities, 
degradation products and matrix components. This definition implies the 
identification tests, purity test and assays. The two drugs have specific λ max. 
2.  Linearity and Range 
The linearity and range of the analytical method is determined from the 
calibration curve and mathematical transformations proportional to the 
concentration of the analyte. The prepared standard stock solution is diluted to 
the concentration ranging from 50 to 150% (of 100% target level) of finasteride 
and Tamsulosin Hydrochloride. The data are presented in the Table No. 3(a) 
and 3 (b). 
3.  Precision (Method Precision, Intermediate Precision (Ruggedness)) 
Precision was evaluated by quantifying homogenous sample in six times 
for both intra-assay and inter-assay precision equivalent to 10µg/ml of 
Finasteride  and 10.8µg/ml of Tamsulosin hydrochloride. 
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The amount of drug present per capsule was calculated by adopting the 
following formula. 
Area of Sample x Standard dilution x Average weight x Potency 
=    _____________________________________________________ 
     Area of Standard x Sample dilution  x 100 
The assay results are presented in the Table No.3 (d) 
4.  Accuracy (Recovery) 
To ensure the accuracy of the method, recovery studies were carried out 
by addition of a known quantity of the standard drug to the pre-analyzed 
samples (50, 100 and 150% of target level) and the whole contents were 
reanalyzed by the proposed method. 
Percentage recovery was calculated by using the following formula:   
     Amt. found in solution – Actual amt. of preanalysed sample  
 =                                                                                                  x 100      
                                Amount of standard added 
The data are presented in Table No. 3(e) and 3(f) 
5.  Stability of drug solution: 
The standard solution and sample solution were scanned after 24 hours 
to study the stability of the analyte in solution. Finasteride and Tamsulosin 
Hydrochloride were stable for up to 24 hours. 
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RESULTS AND DISCUSSION 
1. Reverse Phase High Performance Liquid Chromatography 
method  
The analytical conditions for the HPLC method was established for 
simultaneous estimation of Finasteride and Tamsulosin hydrochloride in 
Pharmaceutical dosage forms. Various mobile phase systems were prepared 
and trials were made to determine appropriate chromatographic conditions.  
Finasteride monograph is official in USP. In context to the method 
specified for the active pharmaceutical ingredient and formulation, this method 
for combination of Finasteride and Tamsulosin Hydrochloride was developed. 
As a result, the method focused on C18 column and mobile phase, Acetonitrile:  
buffer (pH adjusted to 3). Different ratios of this mobile phase, flow rates and 
UV detector wavlength in various combinations were tried out.  
The trials carried out are as follows: 
With ACN: Buffer (75:25 v/v) as mobile phase at 220nm and 1.0ml/min 
flow rate, a trial was carried out. The capacity factor of Tamsulosin 
Hydrochloride was 0.35. Finasteride peak was not significant comparatively. 
Then the flow rate was changed as 0.75ml and UV wavelength to 
230nm. Tamsulosin Hydrochloride achieved a retension time at 2.05 minutes. 
A trial was carried out with ACN: Buffer (50:50 v/v) as mobile phase at 
230nm and 0.75ml flow rate. The retension time of Tamsulosin and Finasteride 
 68
was 2.05 mins and 8.79 minutes respectively. When we applied this Retension 
time, the linearity was narrowed. 
Further a trial was carried out with ACN: Buffer (60:40 v/v) as mobile 
phase at 230nm and 0.75ml flow rate. The retension time of Tamsulosin was 
2.65 mins. The retension time of Finasteride was extended to 7.79 minutes. 
In the expectation of better peak area and resolution, we tried out with 
ACN: Buffer (60:40 v/v) as mobile phase at 240nm and 0.75ml flow rate. But 
we were deprived of achieving the goal as the peak corresponding to 
Tamsulosin was not prominent. 
At last, ACN: Buffer (60:40 v/v) as mobile phase, 230nm as UV 
detector wavelength and 0.8ml flow rate are finalized for the chromatographic 
method. The retention time achieved for Tamsulosin Hydrochloride was 2.65 
minutes and for Finasteride was 7.15 minutes. Total runtime for an injection 
was achieved as 10 minutes. The trials were exhibited as graphs in the 
following pages. 
The System precision achieved was % RSD = 0.1151 and 0.1051 for 
FINA and TAMS respectively< Limit: Not more than 2%>, Tailing factor for 
Finasteride was 1.35 and Tamsulosin Hydrochloride was 1.65 were within the 
limit <Limit: Not more than 2>,  Resolution was 21.4 < Limit: Not less than 
2.0>  & No.of Theoretical plates were 4600 for Tamsulosin Hydrochloride and 
12136 for Finasteride < Limit: Not less than 2500> 
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The Linearity of HPLC method developed for the assay was evaluated 
by injecting mixture of standard drugs, Finasteride and Tamsulosin 
Hydrochloride at a concentration ranging from 50 – 150mcg/ml of Finasteride 
and 4-12mcg/ml of Tamsulosin Hydrochloride. A linearity data indicating the 
slope, y-intercept values, correlation coefficient, LOD and LOQ are presented 
in table no. 1(a) and 1(b). The correlation coefficient was found to be 0.998 
indicating the best linearity. 
The precision for the Finasteride and Tamsulosin Hydrochloride was 
evaluated by using homogeneous sample in six times determinations for both 
intra day and inter day assay (100% target level). The data are presented as 
table No. 1(d). 
The assay of market sample determined the content of Finasteride as 
99.51% (of label claim – 5mg) with a confidence interval of ±0.1568 and the 
content of Tamsulosin Hydrochloride as 99.78% (of label claim – 0.4mg) with 
a confidence interval of ±0.1403 showing good precision. 
The accuracy was determined, for Finasteride and Tamsulosin 
hydrochloride by fortifying sample and standard drug substance at a 
concentration ranging from 50% to 150% of target level. The data are 
presented as 1(e) and 1(f). Overall recovery determined the content of 
Finasteride as 99.69% (of label claim – 5mg) with a confidence interval of 
±0.3124 and the content of Tamsulosin Hydrochloride as 99.2% (of label claim 
– 0.4mg) with a confidence interval of ±0.1797. This indicates that the method 
is capable of   showing good accuracy and reproducibility. 
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2. High Performance Thin Layer Chromatography method  
The analytical conditions for the HPTLC method was established for 
simultaneous estimation of Finasteride and Tamsulosin hydrochloride in 
Pharmaceutical dosage forms. Various mobile phase systems were prepared 
and trials were made to determine appropriate chromatographic conditions. 
Trials were carried out with the prepared TLC plates for determination of Rf of 
individual drugs. 
The trials carried out for optimization of solvents are as follows. 
Trials with the mobile phase of Chloroform: EAC: Ammonia in ratio of 
(7:2.5:0.5) and (6:4:1.5) were carried out. But the two drugs did not resolve 
much. 
Trials with the mobile phase of Chloroform: EAC: water in ratio of 
(6:3:1) and (7:2:1) were carried out. But there was no proper resolution of two 
drugs from the mixture spot. The latter also showed tailing of the spot. 
Trials were made with the mobile phase of Toluene: EAC: Methanol in 
ratio of (6:3:1) and trials were also carried out with Toluene: Chloroform: 
Formic acid (6:3:1). But there was no separation between spots. 
Trials were then made with the mobile phase of Toluene: EAC: Formic 
acid in ratio of (6:3:1). Separation of both drugs was achieved. But the Rf of 
Finasteride was found to be 0.331 and that of Tamsulosin was 0.166.  
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Trials were then made with the mobile phase of Toluene: Chloroform: 
Methanol in ratio of (6:3:1). Separation of both drugs was achieved. But the Rf 
of Finasteride was found to be 0.447 and that of Tamsulosin was 0.282. 
Trials were then made with the mobile phase of Toluene: Chloroform: 
Methanol in ratio of (6:2:2). Separation of both drugs was achieved. But the Rf 
of Finasteride was found to be 0.448 and that of Tamsulosin was 0.293.  
Photo of the chromatogram with spots developed in Iodine chamber is 
exhibited as Photo No.1 in the following pages. 
This combination of mobile phase was finalized for HPTLC and 
proceeded with precoated plates. A streaking was observed with Tamsulosin 
spot, which affected the peak shape.  
Densitogram is presented as Photo No.2 in the following pages. 
Then the ratio of the mobile phase was modified as 
Toluene:Chloroform: Methanol:Triethylamine (6:2:2:1). The scanning of the 
developed plates showed a good peak shape but had the resolution was not 
good. 
Photo of the chromatoplate obtained with the trial is presented as Photo 
No.3 in the following pages along with the corresponding densitogram as Photo 
No.4 
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Then the ratio of the mobile phase was modified as 
Toluene:Chloroform: Methanol:Triethylamine (7:2:1:2). The scanning of the 
developed plates showed a good peak shape and good resolution as well. 
Chromatoplate obtained with the trial (with better resolution of two 
drugs) is presented as Photo No.5 in the following pages along with the 
corresponding densitogram as Photo No.6 
The tailing factor was found to be not more than 2.0 and the Retardation 
factor was more than 0.2. Resolution factor was more than 2.0. The values are 
presented in the Table No.2(g) in the following pages. 
The Linearity of HPTLC method developed for the assay was evaluated 
by injecting mixture of standard drugs, Finasteride and Tamsulosin 
Hydrochloride at a concentration ranging from 500 – 1500mcg/ml of 
Finasteride and 40-120mcg/ml of Tamsulosin Hydrochloride. A summary of 
the data indicating the slope, y-intercept values and correlation coefficient are 
presented in table no. 2(a) and 2(b). The correlation coefficient was found to be 
greater than 0.99. 
The precision for the Finasteride and Tamsulosin Hydrochloride was 
evaluated by using homogeneous sample in six times determinations for 
intraday assay (100% target level). The data are presented as table No. 2(c). 
The assay of market sample determined the content of Finasteride as 
99.68% (of label claim – 5mg) with a confidence interval of ±0.0217 and the 
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content of Tamsulosin Hydrochloride as 99.85% (of label claim – 0.4mg) with 
a confidence interval of ± 0.2791. 
The accuracy was determined, for Finasteride and Tamsulosin 
hydrochloride by fortifying sample and standard drug substance at a 
concentration ranging from 50% to 150% of target level. The data are 
presented as 2(e) and 2(f). Overall recovery determined the content of 
Finasteride as 99.48% (of label claim – 5mg) with a confidence interval of 
±0.2269 and the content of Tamsulosin Hydrochloride as 99.57% (of label 
claim – 0.4mg) with a confidence interval of ±0.3021. 
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 3. UV-Visible Spectrophotometric method (Q absorbance ratio)  
The analytical conditions for the UV Spectroscopy by Q-absorbance 
method was established for simultaneous estimation of Finasteride and 
Tamsulosin Hydrochloride. 
Based on the solubility profile of Finasteride and solubility profile of 
Tamsulosin Hydrochloride, the solvent was devised. The solvent used was 
mixture of ethanol 95%v/v and water in the ratio (3:5). Other ratios were not 
suitable as the drugs had different solubility profiles.  
 λ max of Finasteride was determined as 205nm and λ max  of Tamsulosin 
Hydrochloride was determined as 225nm (presented as Spectrum No. 3(a) and 
3(b) respectively in the following pages. Both the drugs obeyed Beers’ Law 
within the concentration range of 5-30mcg. The Calibration curve and overlay 
spectra for concentrations of the drug within Beer’s Law range are exhibited in 
the following pages as Graph No. 3(a), 3(b), 3(c) and 3(c) and Spectrum No. 
3(a) and 3(b) respectively. 
The overlay spectra of Finasteride and Tamsulosin Hydrochloride with 
the same concentration, determined three isoabsorptive points, which are 
217.7nm, 239nm and 260nm. Of these 217.7nm (as λ1) was suitable for  
Q-absorbance method with  
λ max  of Tamsulosin Hydrochloride (as λ2).  
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Two equations,  
Equation 1: A1 = ax1 (Cx + CY);  
Equation 2: Cx = QM-QY / Qx - QY  x  A1/ ax1],  
were devised based on which the concentration of Finasteride and Tamsulosin 
Hydrochloride in market sample were determined. 
The regression equation was constructed with the slope and intercept 
values obtained from the linearity data. The correlation coefficient of Standard 
drugs were greater than 0.99. LOD, LOQ and Sandell’s sensitivity were 
determined from the linearity and calibration data and presented as Table No. 
3(a) and 3(b). 
The assay of Finasteride was found to be 100.44% and that of 
Tamsulosin Hydrochloride was found to be 100.35% indicating good precision 
and repeatability. 
The recovery studies also show that there is a reliable accuracy 
indicating the %recovery as 100.339% and 99.397% with the confidence 
interval (95%) as ±0.4550 and ±0.32099 for Finasteride and Tamsulosin 
Hydrochloride respectively showing good accuracy.  
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SUMMARY AND CONCLUSION 
 
 
Analysts are forever in search of rapid, sensitive and accurate methods 
of analysis, that are viable in routine quantitative study.  
This project was focused in the method development for the 
simultaneous quantification of the pharmaceutical dosage form of Finasteride 
and Tamsulosin Hydrochloride. It was successful in achieving three different 
analytical techniques, namely, 1) High Performance Liquid Chromatography 
(HPLC), 2) High Performance Thin Layer Chromatography (HPTLC) and  
3) Q-absorbance ratio method by UV Spectroscopy for the routine analysis for 
the combination dosage forms. 
The HPLC method, proved to have high selectivity, precision and 
accuracy. The drugs were eluted by C18, ODS column (Phenomenex), using 
Acetonitrile: Buffer (pH adjusted to 3.0 ± 0.2 with Orthophosphoric acid) in the 
ratio of 60:40 as mobile phase and UV detector at wavelength of 230nm. The 
retension time of Finasteride was 7.11 minutes and that of Tamsulosin 
Hydrochloride was 2.65 minutes. 
The HPTLC method developed for the formulation proved to be easiest 
and quick method of analysis. The method was developed using CAMAG 
HPTLC scanner and Linomat applicator, with a mobile phase combination of 
Toluene: Chloroform: Methanol: Triethylamine in the ratio of 7:2:1:2 at 230nm 
as scanning wavelength. The retardation factor of Tamsulosin Hydrochloride 
was 0.35 and that of Finasteride was 0.78.  
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Q-absorbance ratio method developed for the dosage form, proved to be 
easy and economical method for the rapid evaluation of drug components 
utilizing λmax of Tamsulosin Hydrochloride and Isoabsorptive point of both 
the drugs.  
The linearity data was subjected to linear regression analysis in order to 
confirm the linear relationship between concentration and response. 
All the three analytical techniques developed were subjected to method 
validation as specified in ICH guidelines. The analytical performance 
characteristics were established and the values were found to be within the 
specified limits as recommended.  
Quantitative estimation was subjected to statistical analysis. %RSD 
value obtained was below 2 indicates precision of the method. The low 
standard error value indicates accuracy of the method.  
  Thus the methods developed were found to be simple, specific, precise, 
linear, accurate and were reliable & reproducible for simultaneous 
quantification of Finasteride and Tamsulosin Hydrochloride in pharmaceutical 
dosage forms. 
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Photo No.1 Photo of the chromatogram with spots developed in 
Iodine chamber 
 
 
 
 
 
 
 
 
Photo No.2: Densitogram with improper peak shape 
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Photo No.3: Photo of the Chromato-plate with minimum resolution 
between two drugs (FINA and TAMS) 
 
 
 
Photo No.4: Densitogram corresponding to the Chromato plate in 
Photo No.3 
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Photo No.5: Photo of the chromato- plate with good resolution of 2 
distinct spots of the two drugs 
 
 
 
Photo No.6: Densitogram corresponding to the Chromato plate in 
Photo No.5 
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TABLE NO. 1(a): LINEARITY DATA OF FINASTERIDE (FINA) AND 
TAMSULOSIN HYDROCHLORIDE (TAMS) BY HPLC 
 
Finasteride Tamsulosin Hydrochloride  
S.No Concentration
(mcg/ml) 
Peak Area Concentration
(mcg/ml) 
Peak Area 
1. 50 878.599 4 233.451 
2. 75 1442.121 6 350.144 
3. 100 1801.245 8 466.283 
4. 125 2401.502 10 575.461 
5. 150 2715.651 12 687.236 
 
 
 
 
TABLE NO. 1(b): ANALYTICAL PERFORMANCE PARAMETERS OF 
FINA AND TAMS FOR HPLC 
 
Parameters Finasteride
Tamsulosin 
Hydrochloride 
Slope 18.534 57.313 
y-Intercept -1.989 
 
3.343 
Correlation coefficient 0.9981 0.9998 
Limit of Detection (μg/ml) 10.962 0.193 
Limit of Quantification (μg/ml) 33.218 0.584 
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TABLE NO. 1(c): ANALYSIS OF PHARMACEUTICAL 
FORMULATIONS BY HPLC 
 
 
Label Claim: Finasteride 5mg and Tamsulosin Hydrochloride 0.4mg per 
capsule 
 
FINA TAMS Sample 
No. Amount 
esimated in 
mg/capsule* 
%RSD SE CI Amount 
estimated in 
mg/capsule* 
%RSD SE (95%) 
CI 
1. 5.0014 0.4012 
2. 4.975 0.4006 
3 4.960 
 
0.5858 
 
0.01686 
 
±0.0331 
0.3973 
 
0.5228 
 
0.00121 
 
±0.0024 
 
*Each value is an average of six determinations. 
 
 
TABLE NO. 1(d): 
PRECISION DATA (Repeatability and Intermediate Precision) 
 
 
Sample 
No. 
FINA 
(Amount estimated in 
mg/capsule) 
TAMS 
(Amount estimated in 
mg/capsule) 
 INTRA DAY INTER DAY INTRA DAY INTER DAY 
1. 4.962 5.001 0.3968 0.4012 
2. 4.968 4.997 0.3964 0.4005 
3. 4.9767 4.973 0.3978 0.3978 
4. 4.9975 4.9735 0.4012 0.4018 
5. 4.944 4.960 0.4006 0.3973 
6. 4.9805 4.9725 0.3954 0.4025 
Mean:  4.9754 Mean:  0.3991 
%RSD: 0.3381 %RSD: 0.0024 
SE: 0.005 SE: 0.010 
 (95%)CI: ±0.01 (95%) CI: ±0.0140 
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TABLE NO. 1(e): RECOVERY STUDIES (Accuracy data) 
 
FINA TAMS 1  
Conc. 
levels 
Amt of 
Std 
added 
(mg) 
Amt of Std. 
Recovered 
(mg) 
% 
Recovery
Amt of 
Std 
added 
(mg) 
Amt of Std. 
Recovered 
(mg) 
% 
Recovery
1. 12.53 12.59 100.48 1.010 1.0001 99.02 
2. 12.53 12.563 100.26 1.010 1.0021 99.22 
3. 
 
50% 
12.53 12.535 100.28 1.010 1.0087 99.87 
4. 37.59 37.36 99.39 3.030 3.0187 99.63 
5. 37.59 37.305 99.24 3.030 3.0027 99.10 
6. 
 
100% 
37.59 37.415 99.53 3.030 3.0079 99.27 
7. 62.65 62.125 99.36 5.050 5.0052 99.10 
8. 62.65 62.208 99.29 5.050 5.013 99.28 
9. 
 
150% 
62.65 62.268 99.39 5.050 5.011 99.23 
 
 
TABLE NO. 1(f): EVALUATION OF ACCURACY DATA 
 
S.No. Concentration 
Levels 
% Recovery of FINA % Recovery of TAMS
1. 100.48 99.02 
2. 100.26 99.22 
3. 
 
 
50% 100.28 99.87 
4. 99.39 99.63 
5. 99.24 99.10 
6. 
 
 
100% 99.53 99.27 
7. 99.36 99.10 
8. 99.29 99.28 
9. 
 
 
150% 99.39 99.23 
Mean 99.69 99.30 
%RSD 0.4798 0.2768 
SE 0.1594 0.0917 
(95%) CI ±0.3124 ±0.1797 
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TABLE NO. 1(g): SYSTEM SUITABILITY DATA 
 
Values 
Parameters 
FINA TAMS 
Acceptance Criteria 
% RSD 0.1151 0.1015 Not more than 2.0% 
Theoretical plates 12150 4600 Not less than 2500 
Tailing factor 1.35 1.65 Not more than 2.0 
Resolution 21.4 Not less than 2.0 
 
 
TABLE NO. 2(a): LINEARITY DATA OF FINA AND TAMS  
BY HPTLC 
 
 
Finasteride Tamsulosin Hydrochloride  
S.No Concentration
(mcg/spot) 
Peak Area Concentration
(mcg/spot) 
Peak Area 
1. 12.5 1226.3 1.0 419.0 
2. 18.75 1645.7 1.5 635.3 
3. 25.0 2250.4 2.0 853.2 
4. 31.25 2780.6 2.5 1042.7 
5. 37.5 3340.1 3.0 1261.1 
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TABLE NO. 2(b): ANALYTICAL PERFORMANCE PARAMETERS OF 
FINA AND TAMS FOR HPTLC 
 
 
Parameters Finasteride
Tamsulosin 
Hydrochloride 
Slope 88.168 419.926 
y-Intercept 37.007 2.007 
Correlation coefficient 0.9982 0.9996 
Limit of Detection (μg/spot) 1.770 0.054 
Limit of Quantification (μg/spot) 5.363 0.164 
 
 
TABLE NO. 2(c): ANALYSIS OF PHARMACEUTICAL 
FORMULATIONS BY HPTLC 
 
Label Claim: Finasteride 5mg and Tamsulosin Hydrochloride 0.4mg per 
capsule 
 
 
FINA TAMS Sample 
No. Amount 
esimated in 
mg/capsule* 
%RSD SE CI Amount 
estimated in 
mg/capsule* 
%RSD SE (95%) 
CI 
1. 4.9835 0.4010 
2. 4.974 0.4001 
3 4.9915 
 
0.1758 
 
0.0051 
 
±0.01 
0.3971 
 
0.4793 
 
0.0011 
 
±0.0022 
 
*Each value is an average of six determinations. 
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TABLE NO. 2(d): PRECISION DATA (Intra day Assay) 
 
 
 
Sample 
No. 
FINA 
(Amount estimated in 
mg/capsule) 
TAMS 
(Amount estimated in 
mg/capsule) 
1. 4.9695 0.3976 
2. 5.001 0.3978 
3. 5.024 0.4010 
4. 4.984 0.3987 
5. 4.968 0.3973 
6. 4.957 0.3992 
Mean:  4.9839 Mean:  0.3986 
%RSD: 0.4984 %RSD: 0.3500 
SE: 0.011 SE: 0.1424 
(95%) CI: ±0.02174 (95%) CI: ±0.2791 
 
 
TABLE NO. 2(e): RECOVERY STUDIES (Accuracy data) 
 
FINA TAMS Sample 
No. 
 
Conc. 
levels 
Amt 
of Std 
added 
(mg) 
Amt of 
Std. 
Recovered 
(mg) 
% 
Recovery
Amt 
of Std 
added 
(mg) 
Amt of 
Std. 
Recovered 
(mg) 
% 
Recovery
1. 12.50 12.41 99.26 1.000 1.003 100.35 
2. 12.50 12.395 99.16 1.000 0.995 99.50 
3. 
 
50% 
12.50 12.48 99.88 1.000 0.9889 98.89 
4. 37.50 37.33 99.55 3.000 2.9804 99.35 
5. 37.50 37.155 99.10 3.000 2.997 99.9 
6. 
 
100% 
37.50 37.453 99.87 3.000 2.972 99.10 
7. 62.50 61.90 99.05 5.000 5.015 100.3 
8. 62.50 62.23 99.57 5.000 4.980 99.6 
9. 
 
150% 
62.50 62.43 99.88 5.000 4.957 99.14 
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TABLE NO. 2(f): EVALUATION OF ACCURACY DATA 
 
S.No. Concentration 
Levels 
% Recovery of FINA % Recovery of TAMS
1. 99.26 100.35 
2. 99.16 99.50 
3. 
 
 
50% 99.88 98.89 
4. 99.55 99.35 
5. 99.10 99.9 
6. 
 
 
100% 99.87 99.10 
7. 99.05 100.3 
8. 99.57 99.6 
9. 
 
 
150% 99.88 99.14 
Mean 99.48 99.57 
%RSD 0.3492 0.4644 
SE 0.1158 0.1541 
(95%) CI ±0.2269 ±0.3021 
 
 
TABLE NO. 2(g): SYSTEM SUITABILITY DATA 
 
Values 
Parameters 
FINA TAMS 
Acceptance Criteria 
% RSD 0.4984 0.5014 Not more than 2.0% 
Rf 0.35 0.78 Not less than 0.2 
Tailing factor 0.985 0.92 Not more than 2.0 
Resolution 2.56 Not less than 2.0 
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TABLE NO. 3(a): LINEARITY DATA OF FINA AND TAMS BY 
UV SPECTROPHOTOMETRY 
 
Finasteride Tamsulosin Hydrochloride  
S.No Concentration 
(mg/ml) 
Absorbance 
at λmax 
(205 nm) 
Concentration
(mcg/ml) 
Absorbance at 
λmax (225 nm)
1. 5 0.212 5 0.240 
2. 10 0.389 10 0.372 
3. 15 0.603 15 0.591 
4. 20 0.751 20 0.748 
5. 25 0.972 25 0.942 
6. 30 1.111 30 1.094 
 
 
 
TABLE NO. 3(b): ANALYTICAL PERFORMANCE PARAMETERS OF 
FINA AND TAMS FOR UV SPECTROPHOTOMETRY 
 
 
Parameters Finasteride 
Tamsulosin 
Hydrochloride 
Slope 0.0373 0.0362 
y-Intercept 0.0181 0.0272 
Correlation coefficient 0.9988 0.9985 
Limit of Detection (μg/ml) 1.770 2.024 
Limit of Quantification (μg/ml) 5.363 6.133 
Sandell’s Sensitivity 
(mcg/cm2/0.001) 
0.02559 0.02563 
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TABLE NO. 3(c): ANALYSIS OF PHARMACEUTICAL 
FORMULATIONS BY UV SPECTROPHOTOMETRY 
 
 
Label Claim: Finasteride 5mg and Tamsulosin Hydrochloride 0.4mg per 
capsule 
 
 
FINA TAMS Sample 
No. Amount 
esimated in 
mg/capsule* 
%RSD SE (95%) 
CI 
Amount 
estimated in 
mg/capsule* 
%RSD SE (95%) 
CI 
1. 5.024 0.4012 
2. 5.005 0.4053 
3 5.084 
 
0.8185 
 
0.0238 
 
±0.0466 
0.3998 
 
0.7108 
 
0.0017 
 
±0.0032 
 
*Each value is an average of six determinations. 
 
TABLE NO. 3(d): 
PRECISION DATA (Repeatability and Intermediate Precision) 
 
 
 
Sample 
No. 
FINA 
(Amount estimated in 
mg/capsule) 
TAMS 
(Amount estimated in 
mg/capsule) 
 INTRA DAY INTER DAY INTRA DAY INTER DAY 
1. 5.024 5.001 0.4009 0.4012 
2. 5.005 5.018 0.4050 0.4005 
3. 5.011 5.098 0.3998 0.3987 
4. 5.076 5.0167 0.4015 0.4018 
5. 5.047 4.9899 0.4046 0.3968 
6. 4.989 4.9725 0.4025 0.4031 
Mean:  5.0207 Mean:  0.4014 
%RSD: 0.7297 %RSD: 0.5798 
SE: 0.0106 SE: 0.00067 
(95%) CI: ±0.02073 (95%) CI: ±0.00132 
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TABLE NO. 3(e): RECOVERY STUDIES (Accuracy data) 
 
 
FINA TAMS  
Sample 
No. 
 
Conc. 
levels 
Amt of 
Std 
added 
(mg) 
Amt of Std. 
Recovered 
(mg) 
% 
Recovery 
Amt of 
Std 
added 
(mg) 
Amt of Std. 
Recovered 
(mg) 
% 
Recovery 
1. 2.5 2.525 101.00 2.5 2.491 99.64 
2. 2.5 2.541 101.64 2.5 2.476 99.22 
3. 
 
50% 
2.5 2.498 99.92 2.5 2.457 99.04 
4. 7.5 7.514 100.19 7.5 7.417 98.89 
5. 7.5 7.478 99.71 7.5 7.509 100.12 
6. 
 
100% 
7.5 7.551 100.68 7.5 7.428 99.04 
7. 12.5 12.43 99.44 12.5 12.407 99.26 
8. 12.5 12.57 100.56 12.5 12.53 100.24 
9. 
 
150% 
12.5 12.489 99.91 12.5 12.39 99.12 
 
 
TABLE NO. 3(f): EVALUATION OF ACCURACY DATA 
 
S.No. Concentration 
Levels 
% Recovery of FINA % Recovery of TAMS
1. 101.00 99.64 
2. 101.64 99.22 
3. 
 
 
50% 99.92 99.04 
4. 100.19 98.89 
5. 99.71 100.12 
6. 
 
 
100% 100.68 99.04 
7. 99.44 99.26 
8. 100.56 100.24 
9. 
 
 
150% 99.91 99.12 
Mean 100.339 99.397 
%RSD 0.6941 0.4943 
SE 0.2321 0.1638 
(95%) CI ±0.4550 ±0.32099 
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Graph No. 1(a) 
 
 
Calibration curve of Finasteride by HPLC
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Graph No.1(b) 
 
Residual plot of Finasteride by HPLC
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Graph No.1(c) 
 
Calibration curve of Tamsulosin Hydrochloride by 
HPLC
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Graph No. 1(d) 
 
Residual plot  of Tamsulosin Hydrochloride by 
HPLC
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Graph No. 2(a) 
 
 
Calibration Curve of Finasteride by HPTLC
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Graph No. 2(b) 
 
Residual plot of Finasteride by HPTLC
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Graph No. 2(c) 
 
Calibration curve of Tamsulosin Hydrochloride by 
HPTLC
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Graph No. 2(d) 
 
Residual plot of Tamsulosin hydrochloride by HPTLC
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Graph No. 3(a) 
 
 
Beer's Law Plot of Finasteride by UV 
Spectrophotometry
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Graph No. 3(b) 
 
 
Residual plot of Finasteride by UV 
Spectrophotometry
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Graph No. 3(c) 
 
Beer's Law Plot of Tamsulosin Hydrochloride by 
UV Spectrophotometry
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Graph No. 3(d) 
 
Residual plot of Tamsulosin Hydrochloride by UV 
Spectrophotometry
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TRIALS PERFORMED IN HPLC METHOD DEVELOPMENT 
 
Chromatograph No. 1(a): Trial No.1 
 
 
 
 
Chromatograph No. 1(b): Trial No: 2 
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Chromatograph No. 1(c): Trial No:3 
 
 
 
Chromatograph No. 1(d): Trial No:4 
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Chromatograph No. 1(e): Trial No.5 
 
 
Chromatograph No. 1(f):  Blank 
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Chromatograph No. 1(g): Finasteride Standard 
 
 
 
Chromatograph No. 1(h): Tamsulosin Hydrochloride Standard 
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Chromatograph No. 1(i): Linearity Level 1 
 
 
 
 
 
Peak  
No. 
 
Reten.  
Time 
Area 
[mV.s] 
Height 
[mV] 
W05 
[min] 
Area 
[%] 
Height 
[%] 
1 2.673 233.451 41.4825 0.0867 20.8908 30.8522 
2 7.193 878.599 92.9729 0.1533 79.1092 69.1478 
- Total 1112.050 134.4554    
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Chromatograph No. 1(j): Linearity Level 2 
 
 
 
 
  
Peak  
No. 
 
Reten.  
Time 
Area 
[mV.s] 
Height 
[mV] 
W05 
[min] 
Area 
[%] 
Height 
[%] 
1 2.627 350.144 65.5247 0.0933 19.4441 28.3638 
2 7.113 1442.121 165.4901 0.1533 80.5559 71.6362 
- Total 1792.265 231.0148    
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Chromatograph No. 1(k): Linearity Level 3 
 
 
 
 
 
 
Peak  
No. 
 
Reten.  
Time 
Area 
[mV.s] 
Height 
[mV] 
W05 
[min] 
Area 
[%] 
Height 
[%] 
1 2.613 466.283 90.7033 0.0933 19.3153 28.4172 
2 7.087 1801.245 228.4810 0.1467 80.8647 71.5848 
- Total 2267.528 319.1843    
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Chromatograph No. 1(l): Linearity Level 4 
 
 
 
 
 
 
 
Peak  
No. 
 
Reten. 
Time 
Area 
[mV.s] 
Height 
[mV] 
W05 
[min] 
Area 
[%] 
Height 
[%] 
1 2.633 575.461 102.9119 0.0933 19.4840 28.5675 
2 7.140 2401.502 257.3299 0.1533 80.5160 71.4325 
- Total 2976.963 360.2419    
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Chromatograph No. 1(m): Linearity Level 5 
 
 
 
 
Peak  
No. 
 
Reten.  
Time 
Area 
[mV.s] 
Height 
[mV] 
W05 
[min] 
Area 
[%] 
Height 
[%] 
1 2.620 687.236 122.4690 0.0933 19.4673 28.8397 
2 7.073 2715.651 302.1851 0.1533 80.5327 71.1603 
- Total 3402.887 424.6541    
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Chromatograph No. 1(n): Sample 
 
 
 
Peak  
No. 
 
Reten.  
Time 
Area 
[mV.s] 
Height 
[mV] 
W05 
[min] 
Area 
[%] 
Height 
[%] 
1 2.693 451.461 74.0847 0.0933 17.5183 28.9602 
2 4.847 40.5736 7.6222 0.1067 2.2736 2.9796 
3 5.400 10.9521 2.3996 0.1333 0.6770 0.9380 
4 5.580 23.8283 4.3681 0.1333 1.4357 1.7075 
5 5.773 26.6349 4.4225 0.1400 1.5548 1.7288 
6 6.287 41.3507 5.8115 0.1433 2.1793 2.2718 
7 7.173 1782.1679 157.3299 0.1533 74.3613 61.4141 
- Total 2376.9685 255.8152    
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Chromatograph No. 1(o): Recovery Studies 
 
 
 
 
 
Peak  
No. 
 
Reten.  
Time 
Area 
[mV.s] 
Height 
[mV] 
W05 
[min] 
Area 
[%] 
Height 
[%] 
1 2.680 476.1102 89.9288 0.0867 20.1642 30.4449 
2 4.827 48.4033 6.7695 0.1133 2.0202 2.2919 
3 5.573 34.3325 4.7603 0.1333 1.8504 1.6117 
4 5.760 21.7175 4.1037 0.1467 1.4908 1.3894 
5 6.253 40.1599 5.0916 0.1400 1.8432 1.7239 
7 7.200 1792.1679 184.7145 0.1467 72.6311 62.5382 
- Total 2412.8913 295.3624    
 
 114
Chromatograph No. 2(a): Linearity Level 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chromatograph No. 2(b): Linearity Level 2 
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Chromatograph No. 2(c): Linearity Level 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chromatograph No. 2(d): Linearity Level 4 
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Chromatograph No. 2(e): Linearity Level 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chromatograph No. 2(f): Sample 
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Chromatograph No. 2(f): Recovery Studies 
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Spectrum No.1 (a): λ max of FINA by UV Spectrophotometry 
 
 
 
 
 
 
Spectrum No.1 (b): λ max of TAMS by UV Spectrophotometry 
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Spectrum No.1 (c): Overlay Spectrum Of FINA in concentration 
range obeying Beer’s Law 
 
 
 
Spectrum No.1 (d): Overlay Spectrum Of Tamsulosin Hydrochloride 
in concentration range obeying Beer’s Law 
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Spectrum No.1 (e): Overlay Spectrum Of Finasteride And 
Tamsulosin Hydrochloride Showing Isoabsorptive Points 
 
 
 
 
 
 
  
